Management of androgenetic alopecia

American Journal of Clinical Dermatology

Volumn 1, Issue 3, 2000, Pages 151-158

  Bolduc, Chantal ^a   Shapiro, Jerry ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FINASTERIDE; MINOXIDIL;

ALOPECIA; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; REVIEW;

ALOPECIA; ANDROGEN ANTAGONISTS; FEMALE; FINASTERIDE; HUMANS; MALE; MINOXIDIL;

EID: 0034189182     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001030-00002     Document Type: Article

References (70)

1. Price VH. Treatment of hair loss. N Engl J Med 1999; 23: 341 (13): 964-773
2. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci 1951; 53: 708-28
3. Olsen E. Androgenetic alopecia. In: Olsen E, editor. Disorders of hair growth. New York: McGraw-Hill, 1994: 257
4. Whiting DA. The diagnosis of alopecia. Current concepts. Kalamazoo (MO); Upjohn Company, 1990
5. Rhodes T, Girman CJ, Savin RC, etal. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg 1988: Dec; 24 (12): 1330-2
6. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999 Sep; 141 (3): 398-405
7. Randall V. The use of dermal papilla cells in studies of normal and abnormal hair follicle biology. Dermatol Clin 1996; 14 (4): 585-94
8. Ziller C. Pattern formation in neural crest derivatives. In: Van Neste D, Randall V, editors. Hair research for the next millenium. Amsterdam: Elsevier Science, 1996: 1
9. Uno H, Cappas A, Schlagel C. Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of the stumptailed macaques. Am J Dermatopathol 1985; 7(3): 283-97
10. Shapiro J, Price VH. Hair regrowth: therapeutic agents. Dermatol Clin 1998; 16 (2): 341-56
11. Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995; 98 (1A Suppl.): 95S-8S
12. Kuster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 1984: 11 (5 Pt 1): 921-6
13. Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359-65
14. Chen W, Zouboulis C, Orfanos C. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177-84
15. Sawaya ME, Price VH. Different levels of 5 alpha reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296-300
16. Bingham K, Shaw D. The metabolism of testosterone by human male scalp skin. J Endocrinol 1973; 57: 111-21
17. Itami S, Kurata S, Sonoda T, et al. Mechanism of action of androgen in dermal papilla cells. Ann N Y Acad Sci 1991; 642: 385-95
18. Itami S, Kurata S, Sonoda T, et al. Characterization of 5 alpha reductase in cultured human dermal papilla cells from beard and occipital hair. J Invest Dermatol 1991; 96: 57-60
19. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5 alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213
20. Imperato-McGinley J. 5 alpha reductase deficiency. Curr Ther Endocrinol Metab 1994; 5: 351-4
21. Price VH. Testosterone metabolism in the skin: a review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens. Arch Dermatol 1975; 111: 1496-502
22. Sawaya ME, Price VH, Harris K. Human hair follicle aromatase activity in females with androgenetic alopecia [abstract]. J Invest Dermatol 1990; 94: 575
23. Randall VA, Thornton MJ, Messenger A. Cultured dermal papilla cells from androgen-dependent human hair follicles contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol 1992; 133: 141
24. Sawaya ME. Purification of androgen receptors in human sebocytes and hair. J Invest Dermatol 1992; 98 (6 Suppl.): 92S-96S
25. Price VH, Menefee E. Quantitative estimation of hair growth: comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. In: Van Neste D, Randall V, editors. Hair research for the next millenium. Amsterdam: Elsevier Science, 1996: 67
26. Sawaya ME. Novel agents for the treatment of Alopecia. Seminars in Cutaneous Medicine and Surgery 1998; 17 (4): 276-83
27. Baden H, Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol 1983; 81: 558-60
28. Kiesewetter F, Langer P, Schell H. Minoxidil stimulates mouse vibrissae follicles in organ culture [letter]. J Invest Dermatol 1991; 96: 295-6
29. Ohtsuyama M, Morhashi M. Minoxidil sulfate effect of internal calcium of cell in the epidermis and epidermal appendages. In: Van neste D, Randall V, editors. Hair research a for the next millenium. Amsterdam: Elsevier Science, 1996: 481
30. Buhl A. Minoxidil's action in hair follicles. J Invest Dermatol 1991; 96: 73S-4S
31. Buhl A, Waldon D, Kawabe T, et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol 1985; 84: 358-20
32. Philpott M, Sanders D, Kealy T. Whole follicular culture. Dermatol Clin 1996; 14: 595-607
33. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41 (5): 717-21
34. Olsen E. Treatment of androgenetic alopecia with topical minoxidil. Resid Staff Physician 1989; 35: 53
35. Olsen E, Weiner MS, Amara I, et al. Five year follow of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol 1990; 22: 643-6
36. Olsen E, DeLong E, Weiner M. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol 1987; 16: 688-95
37. Olsen E, Weiner MS. Topical minoxidil in male pattern hair loss: effects of discontinuation of treatment. J Am Acad Dermatol 1987; 17: 97-101
38. Price VH, Menefee E. Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 1990; 95: 683-7
39. Diani A, Mulholland MJ, Shull KL, et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha reductase inhibitor, alone and in combination with topical minoxidil in the balding stump-tailed macaque. J Clin Endocrinol Metab 1992; 74: 345-50
40. Canadian Pharmacists Association. Monography. Compendium of pharmaceuticals and specialties (CPS). 34th Ed. Ottawa, Canada: Canadian Pharmacists Association, 1999
41. Katz HI, Hien NT, Prawer SE. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol 1987; 16 (3): 711-8
42. Ebsser H, Muller E. Allergic contact dermatitis from minoxidil. Contact Dermatitis 1995; 32: 316-7
43. Kaufman K. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 1996; 14: 697-711
44. Kaufman K. Clinical studies on the effects of oral finasteride, a type II 5 alpha reductase inhibitor, on scalp hair in men with male pattern baldness. In: Van Neste D, Randall V, editors. Hair research for the next millenium. Amsterdam: Elsevier Science, 1996: 363
45. Gormley G, Stoner E, Bruskewitz R, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91
46. Stoner E. The clinical development of 5 alpha reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990; 37: 375-8
47. Dallob A, Sadick N, Unger W, et al. The effects of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydroterstosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703-6
48. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in male with androgenetic alopecia. J Am Acad Dermatol 1999; 41 (4): 550-4
49. Leyden J, Dunlop F, Miller B, et al. Finasteride in the treatment of male with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40 (6): 930-7
50. Kaurman K. Treatment with finasteride 1 mg per day in men with male pattern hair loss. Australas J Dermatol 1997; 38: 20
51. Waldstreicher J. The effects of finasteride in men with frontal male pattern hair loss. Australas J Dermatol 1997; 38: 101
52. Roberts J, Hordinsky MK, Olsen EA, et al. The effects of finasteride on post-menopausal women with androgenetic alopecia [abstract]. Hair Workshop; 1998 May 2-3: Brussels: 16-7
53. Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999 Oct; 162 (4): 1295-300
54. Matzkin H, Barak M, Braf Z. Effect of finasteride on free and total serum prostate specific antigen in men with benign prostatic hypertrophy. Br J Urol 1996; 78: 405-8
55. Hammerstein J, Meckies J, Leo-Rossberg I, et al. Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J Steroid Biochem Mol Biol 1975; 6: 827-36
56. Namer M. Clinical applications of antiandrogens. J Steroid Biochem Mol Biol 1988; 31: 719-29
57. Shaw J. Antiandrogen therapy in dermatology. Int J Dermatol 1996; 35 (11): 770-8
58. Dawber RPR, Sonnex T, Ralfs I. Oral antiandrogen treatment of common baldness in women. Br J Dermatol 1982; 107 Suppl. 22: 20-23
59. Ekoe J, Burckhardt P, Ruedi B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 1980; 160: 398-404
60. Mortimer C, Rushton H, James K. Effective medical treatment for common baldness in women. Clin Exp Dermatol 1984; 9: 342-50
61. Neumann F. Pharmacology and potential use of cyproterone acetate. Horm Metab Res 1977; 9: 1-13
62. Simpson N. The management of androgenetic alopecia in women. J Dermatol Treatment 1989; 1: 107-13
63. Corbol P, Michard A, Minard J, et al. Antiandrogenic effect of spironolactone: mechanism of action. Endoctinology 1975; 97: 52-8
64. Lobo RA, Shoupe D, Serafini P, et al. the effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985; 43: 200-5
65. Loriaux D. Spironolactone and endocrine dysfunction (NIH conference). Ann Intern Med 1976; 85: 630
66. Burke B, Cunliffe W. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 11 (1): 124-5
67. Rushton D. Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia. J Socv Cosmet Chem 1991; 42: 317
68. Elias P. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 1986; 15: 797-809
69. Sporn M, Roberts A, Roche N, et al. Mechanism of action of retinoids. J Am Acad Dermatol 1986; 15: 756-64
70. Bazzano G, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 1986; 15 (Pt 2): 880-3, 890-3